Immatics (IMTX) Stock: Charts & Financials

Immatics N.V.(IMTX)

Biotechnology · Tübingen, BW

$7.64-0.10 (-1.23%)

Delayed quote: Oct 6, 2026, 11:20 AM EDT

About Immatics N.V.

Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.

Tübingen, BW

704 employees

www.immatics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Harpreet Singh

View full financials

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	48.54M	10.44M	8.79M	23.21M	6.09M	5.58M	20.10M	58.25M	56.29M
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	48.54M	10.44M	8.79M	23.21M	6.09M	5.58M	20.10M	58.25M	56.29M
Gross Profit Margin	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
Total Operating Expenses	311.39M	87.20M	85.12M	68.88M	70.19M	68.20M	58.35M	57.31M	55.72M
Research & Development	253.33M	71.28M	68.38M	58.31M	55.35M	53.17M	45.32M	43.33M	43.32M
Selling, General & Administrative	63.61M	15.92M	16.77M	16.05M	14.87M	15.06M	13.05M	14.00M	12.42M
Operating Income (EBIT)	-262.86M	-76.76M	-76.33M	-45.67M	-64.10M	-62.62M	-38.26M	935K	572K
Operating Margin	-541.6%	-735.0%	-867.9%	-196.8%	-1053.3%	-1121.5%	-190.4%	1.6%	1.0%
Income Before Tax (EBT)	-239.65M	-71.69M	-66.73M	-41.77M	-59.46M	-84.10M	-44.18M	44.81M	-2.62M
Interest Income	16.65M	3.75M	4.14M	4.17M	4.59M	5.02M	5.91M	7.06M	6.15M
Interest Expense	1.01M	232K	245K	261K	271K	288K	269K	240K	262K
Other Income/Expense	23.20M	5.07M	9.59M	3.90M	4.65M	-21.48M	-5.92M	43.87M	-3.19M
Net Income	-239.41M	-71.38M	-66.79M	-41.93M	-59.31M	-82.92M	-43.10M	46.46M	-9.54M
Income Tax Expense	-245K	-313K	60K	157K	-149K	-1.18M	-1.07M	-1.65M	6.92M
Net Profit Margin	-493.3%	-683.4%	-759.5%	-180.6%	-974.5%	-1485.1%	-214.5%	79.8%	-17.0%
EBITDA	-248.85M	-73.27M	-73.12M	-41.95M	-60.51M	-59.05M	-34.86M	4.12M	3.95M
EBITDA Margin	-512.7%	-701.6%	-831.4%	-180.7%	-994.2%	-1057.7%	-173.5%	7.1%	7.0%
Depreciation & Amortization	14.01M	3.49M	3.21M	3.72M	3.60M	3.57M	3.40M	3.19M	3.38M
EPS Basic	-1.84	-0.53	-0.50	-0.33	-0.49	-0.68	-0.36	0.48	-0.09
EPS Diluted	-1.84	-0.53	-0.50	-0.33	-0.49	-0.68	-0.36	0.48	-0.12
Weighted Average Basic Shares	136.68M	136.68M	134.64M	126.05M	121.56M	121.55M	121.55M	105.75M	105.88M
Weighted Average Diluted Shares	136.68M	136.68M	134.64M	126.05M	121.56M	121.55M	121.55M	106.80M	110.30M

Quarterly Report

TTM

Quarter ended Jun 2026

Quarter ended Mar 2026

Quarter ended Dec 2025

Quarter ended Sep 2025

Quarter ended Jun 2025

Quarter ended Mar 2025

Quarter ended Dec 2024

Quarter ended Sep 2024

Revenue

48.54M

10.44M

8.79M

23.21M

6.09M

5.58M

20.10M

58.25M

56.29M

Cost of Goods Sold

0.00

Gross Profit

48.54M

10.44M

8.79M

23.21M

6.09M

5.58M

20.10M

58.25M

56.29M

Gross Profit Margin

100.0%

Total Operating Expenses

311.39M

87.20M

85.12M

68.88M

70.19M

68.20M

58.35M

57.31M

55.72M

Research & Development

253.33M

71.28M

68.38M

58.31M

55.35M

53.17M

45.32M

43.33M

43.32M

Selling, General & Administrative

63.61M

15.92M

16.77M

16.05M

14.87M

15.06M

13.05M

14.00M

12.42M

Operating Income (EBIT)

-262.86M

-76.76M

-76.33M

-45.67M

-64.10M

-62.62M

-38.26M

935K

572K

Operating Margin

-541.6%

-735.0%

-867.9%

-196.8%

-1053.3%

-1121.5%

-190.4%

1.6%

1.0%

Income Before Tax (EBT)

-239.65M

-71.69M

-66.73M

-41.77M

-59.46M

-84.10M

-44.18M

44.81M

-2.62M

Interest Income

16.65M

3.75M

4.14M

4.17M

4.59M

5.02M

5.91M

7.06M

6.15M

Interest Expense

1.01M

232K

245K

261K

271K

288K

269K

240K

262K

Other Income/Expense

23.20M

5.07M

9.59M

3.90M

4.65M

-21.48M

-5.92M

43.87M

-3.19M

Net Income

-239.41M

-71.38M

-66.79M

-41.93M

-59.31M

-82.92M

-43.10M

46.46M

-9.54M

Income Tax Expense

-245K

-313K

60K

157K

-149K

-1.18M

-1.07M

-1.65M

6.92M

Net Profit Margin

-493.3%

-683.4%

-759.5%

-180.6%

-974.5%

-1485.1%

-214.5%

79.8%

-17.0%

EBITDA

-248.85M

-73.27M

-73.12M

-41.95M

-60.51M

-59.05M

-34.86M

4.12M

3.95M

EBITDA Margin

-512.7%

-701.6%

-831.4%

-180.7%

-994.2%

-1057.7%

-173.5%

7.1%

7.0%

Depreciation & Amortization

14.01M

3.49M

3.21M

3.72M

3.60M

3.57M

3.40M

3.19M

3.38M

EPS Basic

-1.84

-0.53

-0.50

-0.33

-0.49

-0.68

-0.36

0.48

-0.09

EPS Diluted

-1.84

-0.53

-0.50

-0.33

-0.49

-0.68

-0.36

0.48

-0.12

Weighted Average Basic Shares

136.68M

134.64M

126.05M

121.56M

121.55M

105.75M

105.88M

Weighted Average Diluted Shares

136.68M

134.64M

126.05M

121.56M

121.55M

106.80M

110.30M

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	56.69M	161.37M	59.60M	184.92M	39.57M	38.18M	20.70M	4.31M
Cost of Goods Sold	0.00	0.00	0.00	0.00	0.00	81.95M	44.99M	38.88M
Gross Profit	56.69M	161.37M	59.60M	184.92M	39.57M	-43.77M	-24.29M	-34.56M
Gross Profit Margin	100.0%	100.0%	100.0%	100.0%	100.0%	-114.7%	-117.3%	-801.1%
Total Operating Expenses	270.49M	201.35M	171.88M	152.87M	137.81M	41.39M	57.75M	43.70M
Research & Development	215.93M	153.33M	130.97M	114.25M	99.69M	81.95M	44.99M	38.88M
Selling, General & Administrative	60.12M	48.10M	42.16M	38.65M	38.49M	41.76M	13.19M	8.77M
Operating Income (EBIT)	-213.79M	-39.99M	-112.28M	32.05M	-98.23M	-85.16M	-37.05M	-39.38M
Operating Margin	-377.1%	-24.8%	-188.4%	17.3%	-248.2%	-223.1%	-178.9%	-912.7%
Income Before Tax (EBT)	-233.08M	22.10M	-107.06M	44.98M	-106.25M	-258.78M	-36.46M	-37.03M
Interest Income	20.18M	25.89M	15.28M	2.65M	151K	685K	887K	580K
Interest Expense	1.11M	917K	917K	1.11M	644K	N/A	191K	18K
Other Income/Expense	-19.29M	62.09M	5.22M	12.93M	-8.02M	-173.62M	590K	2.35M
Net Income	-230.74M	15.76M	-104.47M	29.64M	-106.25M	-258.10M	-35.62M	-35.99M
Income Tax Expense	-2.34M	6.35M	-2.59M	15.34M	0.00	0.00	0.00	0.00
Net Profit Margin	-407.0%	9.8%	-175.3%	16.0%	-268.5%	-676.0%	-172.0%	-834.1%
EBITDA	-199.23M	-27.33M	-104.29M	39.50M	-92.25M	-82.44M	-32.73M	-36.81M
EBITDA Margin	-351.4%	-16.9%	-175.0%	21.4%	-233.1%	-215.9%	-158.1%	-853.1%
Depreciation & Amortization	14.56M	12.66M	7.98M	7.45M	5.99M	2.72M	4.32M	2.57M
EPS Basic	-1.81	0.14	-1.30	N/A	-1.68	-5.37	-0.56	-0.57
EPS Diluted	-1.81	0.14	-1.30	N/A	-1.68	-5.37	-0.56	-0.57
Weighted Average Basic Shares	122.35M	106.80M	80.55M	66.99M	62.91M	48.00M	62.91M	62.91M
Weighted Average Diluted Shares	122.35M	106.80M	80.55M	68.21M	62.91M	48.00M	62.91M	62.91M

Annual Report

12/31/2025

12/31/2024

12/31/2023

12/31/2022

12/31/2021

12/31/2020

12/31/2019

12/31/2018

Revenue

56.69M

161.37M

59.60M

184.92M

39.57M

38.18M

20.70M

4.31M

Cost of Goods Sold

0.00

81.95M

44.99M

38.88M

Gross Profit

56.69M

161.37M

59.60M

184.92M

39.57M

-43.77M

-24.29M

-34.56M

Gross Profit Margin

100.0%

-114.7%

-117.3%

-801.1%

Total Operating Expenses

270.49M

201.35M

171.88M

152.87M

137.81M

41.39M

57.75M

43.70M

Research & Development

215.93M

153.33M

130.97M

114.25M

99.69M

81.95M

44.99M

38.88M

Selling, General & Administrative

60.12M

48.10M

42.16M

38.65M

38.49M

41.76M

13.19M

8.77M

Operating Income (EBIT)

-213.79M

-39.99M

-112.28M

32.05M

-98.23M

-85.16M

-37.05M

-39.38M

Operating Margin

-377.1%

-24.8%

-188.4%

17.3%

-248.2%

-223.1%

-178.9%

-912.7%

Income Before Tax (EBT)

-233.08M

22.10M

-107.06M

44.98M

-106.25M

-258.78M

-36.46M

-37.03M

Interest Income

20.18M

25.89M

15.28M

2.65M

151K

685K

887K

580K

Interest Expense

1.11M

917K

1.11M

644K

N/A

191K

18K

Other Income/Expense

-19.29M

62.09M

5.22M

12.93M

-8.02M

-173.62M

590K

2.35M

Net Income

-230.74M

15.76M

-104.47M

29.64M

-106.25M

-258.10M

-35.62M

-35.99M

Income Tax Expense

-2.34M

6.35M

-2.59M

15.34M

0.00

Net Profit Margin

-407.0%

9.8%

-175.3%

16.0%

-268.5%

-676.0%

-172.0%

-834.1%

EBITDA

-199.23M

-27.33M

-104.29M

39.50M

-92.25M

-82.44M

-32.73M

-36.81M

EBITDA Margin

-351.4%

-16.9%

-175.0%

21.4%

-233.1%

-215.9%

-158.1%

-853.1%

Depreciation & Amortization

14.56M

12.66M

7.98M

7.45M

5.99M

2.72M

4.32M

2.57M

EPS Basic

-1.81

0.14

-1.30

N/A

-1.68

-5.37

-0.56

-0.57

EPS Diluted

-1.81

0.14

-1.30

N/A

-1.68

-5.37

-0.56

-0.57

Weighted Average Basic Shares

122.35M

106.80M

80.55M

66.99M

62.91M

48.00M

62.91M

Weighted Average Diluted Shares

122.35M

106.80M

80.55M

68.21M

62.91M

48.00M

62.91M

Income Statement

Quarterly Income Statement (USD)

Annual Income Statement (USD)